Meticulous planning is key to ensuring the COVID-19 vaccines reach all priority groups, wherever they are, in
every single African country.
The state of pharmaceutical manufacturing in East Africa varies from country to country, but the region is unified in its commitment to enhance progress toward localising production.
On Thursday 25th March 2021, Africa Health Business convened a group of stakeholders from the African investment space, representing the African Development Bank (AfDB), MyDawa, GE Health, Metropolitan Hospital, and Chemonics International.
An inspection of the African health sector reveals a mixed picture. There is much to be optimistic about, yet there are still significant challenges. Despite having 14% of the world’s population, the continent bears 25% of the global disease burden.
Some 80 million babies around the world are at higher risk of diseases like diphtheria, measles, and polio as the coronavirus pandemic hinders routine vaccination.
The journey toward UHC is incredibly complex and important. The COVID-19 pandemic has highlighted the already-existing gaps in the health sector, reinforcing how essential it is to establish well-functioning health systems.